150 related articles for article (PubMed ID: 22254256)
21. Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients.
Mohammadpour AH; Nazemian F; Khaiat MH; Tafaghodi M; Salari P; Charkazi S; Naghibi M; Shamsara J
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):73-8. PubMed ID: 24434385
[TBL] [Abstract][Full Text] [Related]
22. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients.
Hung SC; Tung TY; Yang CS; Tarng DC
Am J Kidney Dis; 2005 Jun; 45(6):1073-83. PubMed ID: 15957137
[TBL] [Abstract][Full Text] [Related]
23. Assessment of the impact of weekly versus monthly erythropoiesis stimulating protein therapy on patients with CKD and their families.
Globe D; Glidden D; Hertel J; Thomas J; Ackerman M; Chidolue F; Blanco B; Borden A; Goss TF; Xu X; Kewalramani R
Nephrol Nurs J; 2007; 34(2):151-61. PubMed ID: 17486946
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human erythropoietin treatment of anemia in renal transplant patients.
Lezaic V; Djukanovic L; Pavlovic-Kentera V
Ren Fail; 1995 Nov; 17(6):705-14. PubMed ID: 8771243
[TBL] [Abstract][Full Text] [Related]
25. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.
Lui SF; Wong KC; Li PK; Lai KN
Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366
[TBL] [Abstract][Full Text] [Related]
26. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
29. Influence of erythropoietin treatment on 2,3-bisphosphoglycerate and O2-affinity of red blood cells in children with renal anemia.
Rapoport I; Engelhardt I; Drung I; Holzhütter H; Schmidt G
Biomed Biochim Acta; 1990; 49(2-3):S280-3. PubMed ID: 2386518
[TBL] [Abstract][Full Text] [Related]
30. Liver iron is a major regulator of hepcidin gene expression via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with high rHuEPO doses.
Ribeiro S; Garrido P; Fernandes J; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
Biofactors; 2016 May; 42(3):296-306. PubMed ID: 26990350
[TBL] [Abstract][Full Text] [Related]
31. Response to erythropoietin in pediatric patients with chronic kidney disease: insights from an in vitro bioassay.
Gavish R; Watad S; Ben-Califa N; Goldberg OJ; Haskin O; Davidovits M; Koren G; Falush Y; Neumann D; Krause I
Pediatr Nephrol; 2018 Nov; 33(11):2123-2129. PubMed ID: 30030607
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
[TBL] [Abstract][Full Text] [Related]
33. End-stage renal disease following polycythemia vera: in vitro and in vivo response of erythroid progenitors to erythropoietin and effects of sera on normal erythropoiesis.
Shih LY; Huang JY
Nephron; 1998; 79(2):142-7. PubMed ID: 9647492
[TBL] [Abstract][Full Text] [Related]
34. Management of anaemia in renal failure.
Macdougall I
EDTNA ERCA J; 1999; 25(1):19-22. PubMed ID: 10418372
[TBL] [Abstract][Full Text] [Related]
35. The hematopoietic effect of Epotin (recombinant human erythropoietin-alpha) on maintenance hemodialysis end-stage kidney disease patients.
Al-Shohaib S; Shaker DS; Ghaedi BB; Alyarim M; Emara S; Behairy M
Transplant Proc; 2010 Apr; 42(3):753-9. PubMed ID: 20430164
[TBL] [Abstract][Full Text] [Related]
36. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
37. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
[TBL] [Abstract][Full Text] [Related]
38. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.
Gaweda AE; Goldsmith LJ; Brier ME; Aronoff GR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):576-81. PubMed ID: 20110344
[TBL] [Abstract][Full Text] [Related]
39. Target-based Anemia Management with Erythropoiesis Stimulating Agents (Risks and Benefits Relearned) and Iron (Still More to Learn).
Stivelman JC
Semin Dial; 2017 Mar; 30(2):142-148. PubMed ID: 28083917
[TBL] [Abstract][Full Text] [Related]
40. Improvement of anemia in W/WV mice by recombinant human erythropoietin (rHuEPO) mediated through EPO receptors with lowered affinity.
Kabaya K; Akiyama H; Nishi N; Misaizu T; Okada Y; Kawagishi M; Amano K; Kusaka M; Seki M; Uzumaki H
Life Sci; 1995; 57(11):1067-76. PubMed ID: 7658914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
